FGFR3 and in situ carcinoma: Nevertheless, miR-145 suppressed FGFR3 as a direct target; thus, regardless of the FGFR3 mutation/expression status, miR-145-based therapy may be effective against a broad spectrum of NMIBCs, including different UROMOL2021 classes (classes 1, 2a/b, and 3) and TNM subtypes (Ta and CIS), via the combined inhibition of c-Myc/cyclin D1, FGFR3, and the activation of IFN signaling.